Recruiting OBSERVATIONAL NCT06122285

Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD) (D-SHIELD)

Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy: a Multicenter Prospective Real Life Data Study

Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Conditions Hepatitis D

Interventions Bulevirtide

Updated 5 times since 2023 Last updated: Jan 8, 2025 Started: May 1, 2023 Primary completion: Nov 1, 2023 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06122285, this observational or N/A phase trial focuses on Hepatitis D and remains actively recruiting participants. Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, it has been updated 5 times since 2023, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Feb 2025 — Present [monthly]

Recruiting
Sep 2024 — Feb 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Jun 2024 — Jul 2024 [monthly]

Recruiting
Dec 2023 — Jun 2024 [monthly]

Recruiting

First recorded

May 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Data source: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Milan, Italy